GRAIL Inc. logo GRAL - GRAIL Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 4
HOLD 3
SELL 0
STRONG
SELL
0
| PRICE TARGET: $65.17 DETAILS
HIGH: $80.00
LOW: $56.00
MEDIAN: $62.50
CONSENSUS: $65.17
UPSIDE: 1.16%

About GRAIL Inc. (http://www.grail.com)

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Key Executives

NAME TITLE DOB SALARY
Robert Ragusa Advisor 1960 $1,616,399 USD
Aaron Freidin CFO & Head of Corporate Development 1979 $1,134,942 USD
Joshua J. Ofman Chief Executive Officer & Director 1965 $1,123,985 USD
Abram Barth Chief Legal Officer & Corporate Secretary
Alexis Tosti Vice President of Strategy & Corporate Development
Alison Highlander Chief People Officer
Andrew John Partridge Chief Growth Officer 1969
Eric T. Fung Senior Vice President of Clinical Development 1970
Erin Polak Senior Vice President of Government Affairs, Policy, and Alliance Development
Paul Ciccolella Senior Vice President of Global Development & Operations
Satnam Alag Chief Technology Officer
Sir Harpal S. Kumar Chief Scientific Officer and President of Global Clinical & Medical Affairs
Trish Rowland Senior Vice President of Corporate Communications

Company Peers

Peer analysis pending, check back in 1-2 minutes.